Cereno Scientific strengthens patient engagement and EPIMODE recruitment foundations at Global PH Summit

By Modular Finance22 hours ago Updated

Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments for rare cardiovascular and pulmonary diseases, has been invited to present the Company and its global Phase IIb trial EPIMODE at the Global PH Summit (GPHS), held November 4–7, 2026, in Barcelona, Spain. The participation marks an important step in strengthening Cereno's presence in the international pulmonary hypertension (PH) community, advancing patient-centered drug development and building a strong foundation for effective patient recruitment in the EPIMODE trial.

Organized by PHA Europe & Global, the annual summit brings together representatives from national pulmonary hypertension (PH) patient organizations worldwide, alongside pharmaceutical companies and other key stakeholders in the PH field. Cereno will present and engage directly with patient representatives, including those from countries participating in the EPIMODE trial. The summit offers an important opportunity to deepen these relationships, increase awareness of Cereno's pioneering research and strengthen its position in the global PH landscape.

"We are excited to present CS1 and EPIMODE at this important global gathering. As we advance our Phase IIb program, strengthening our connections with the international patient community is a strategic priority to build momentum around the trial and create the best possible conditions for its successful execution," said Sten R. Sörensen, CEO of Cereno Scientific.

Patient engagement supporting EPIMODE recruitment
Cereno Scientific's lead drug candidate CS1 is being developed as a potentially disease-modifying treatment for pulmonary arterial hypertension (PAH). CS1 is a well-tolerated oral therapy with a favorable safety profile that has shown encouraging efficacy signals in a Phase IIa trial in patients with PAH, including improvements in right heart function, functional class and patient quality of life, with early signs consistent with reverse vascular remodeling.

The Company sees its growing engagement with the patient community as an important foundation for recruitment excellence in the EPIMODE trial. Through closer collaboration with national patient organizations in countries participating in the trial, the Company aims to better understand local patient needs, adapt its communications and extend its reach within local PAH communities. By coordinating these efforts with investigators and participating clinical sites, Cereno aims to increase awareness and understanding of EPIMODE, reach more patients with relevant study information and create the best possible conditions for effective recruitment.

“Working with patient organizations globally, regionally and locally allows us to tailor our approach to the needs of different patient communities. Together with our investigators and clinical centers, we aim to translate these relationships into effective patient outreach and strong trial execution," said Rahul Agrawal, Chief Medical Officer and Head of R&D at Cereno Scientific.

Participation at the Global PH Summit further strengthens Cereno's expanding international network across patient, clinical and scientific communities, supporting its ambition to become an increasingly significant contributor to advancing new treatments for cardiopulmonary disease with high unmet needs.

About the EPIMODE trial
EPIMODE is a global, randomized, double-blind, placebo-controlled, dose-finding Phase IIb trial designed to evaluate the efficacy of CS1 when added to standard of care and identify the optimal dose for continued development, alongside evaluating safety and tolerability and further assessing CS1’s potential disease-modifying effects. The primary endpoint is pulmonary vascular resistance (PVR) measured after the first treatment period of nine months. PVR is a key measure of resistance in the blood vessels of the lungs and is a fundamental measure in PAH, where increased pulmonary resistance and pressure place strain on the right side of the heart. Other measures will also be evaluated including right-heart function, functional capacity, risk evaluation, biomarker changes, clinical worsening, patient-reported outcomes, and pharmacokinetics. A differentiated two-stage trial design is utilized that enables the assessment of how treatment effects develop following continued CS1 treatment or a switch between CS1 and placebo, providing additional insights into the potential durability of CS1’s disease-modifying treatment profile. The trial is designed to enroll approximately 126 patients across approximately 68 investigational sites in 12 countries in North America, Europe and South America. The top-line results are anticipated in Q4 2028, subject to recruitment timelines. The Phase IIb trial has been named EPIMODE, reflecting the scientific foundation of the CS1 program and Cereno Scientific’s focus on epigenetic modulation in cardiopulmonary diseases. More information is available on Clinicaltrials.gov: NCT07761572.

About Cereno Scientific AB
Cereno Scientific is pioneering treatments to enhance and extend life. The company’s innovative pipeline offers disease-modifying drug candidates to empower people suffering from rare cardiovascular and pulmonary diseases to live life to the fullest.

Lead candidate CS1 is an HDAC inhibitor that works through epigenetic modulation and represents a novel therapeutic approach by targeting the underlying mechanisms of pulmonary arterial hypertension (PAH). CS1 is a well-tolerated oral therapy with a favorable safety profile that has shown encouraging efficacy signals in a Phase IIa trial in patients with PAH, including improvements in right heart function, functional class, risk score and patient quality of life, with early signs consistent with reverse vascular remodeling. An Expanded Access Program confirmed CS1 to be well-tolerated with a favorable safety profile over 12 months of treatment and showed that a majority of patients completing treatment maintained or improved clinical status. CS1 is currently being evaluated in EPIMODE, a global, placebo-controlled Phase IIb trial in PAH. CS014 is a new chemical entity and HDAC inhibitor with a multimodal mechanism of action as an epigenetic modulator having the potential to address the underlying pathophysiology of a range of cardiovascular and pulmonary diseases with high unmet needs. CS014 showed a favorable safety and tolerability profile in Phase I, and is being advanced through a streamlined, FDA-aligned pathway toward Phase IIb in pulmonary hypertension associated with interstitial lung disease (PH-ILD). Cereno Scientific is also advancing the preclinical program CS585, an oral, highly potent and selective prostacyclin (IP) receptor agonist shown to prevent thrombosis without increased bleeding risk, currently being evaluated in antiphospholipid syndrome (APS).

The Company is headquartered in GoCo Health Innovation City in Gothenburg, Sweden, and has a US subsidiary, Cereno Scientific Inc., located in Kendall Square, Boston. Cereno Scientific is listed on the Nasdaq First North (CRNO B). The Company’s Certified Adviser is DNB Carnegie Investment Bank AB, certifiedadviser@carnegie.se. More information can be found on www.cerenoscientific.com.